Skip to content

PHARMACON

Active
KBO/BCE: BE 0457.066.176
Watch Print / PDF
Full dossier in preparation

Checked processes every Belgian company, act by act, from the Belgian Official Gazette. The data below is real and verified, this company's full, act-by-act verified dossier is still being assembled.

Process with priority Sign in free to move this company to the front.
Age30 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of PHARMACON is 0.1% (very low). The 2024 annual accounts show equity of €309k and a net result of €-30k. Equity remains stable across the filed fiscal years (±0.4% per year). Its solvency ranks better than 44% of 12464 sector peers (fiscal year 2024). The company has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 7 annual accounts.

Signals

1 signal · with evidence
Persistent losses
Two consecutive loss-making years (2023 and 2024); equity fell accordingly. May indicate structural pressure on profitability.
View the result trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide
Deadline passed, not yet counted as missing
The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 12 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.
Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 31-07-2025, 0 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
How we compute the deadline
The year end is derived from 10 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 nothing on record not filed -
31-12-2024 31-07-2025 31-07-2025 on the day 2025-00363599
31-12-2023 31-07-2024 30-08-2024 30 d late 2024-00410682
31-12-2022 31-07-2023 16-08-2023 16 d late 2023-00331234
31-12-2021 31-07-2022 29-08-2022 29 d late 2022-20416426
31-12-2020 31-07-2021 16-08-2021 16 d late 2021-49900531
31-12-2019 31-07-2020 13-08-2020 13 d late 2020-41800119
31-12-2018 31-07-2019 12-08-2019 12 d late 2019-47400389
31-12-2017 31-07-2018 07-08-2018 7 d late 2018-45300249
31-12-2016 31-07-2017 22-08-2017 22 d late 2017-46600202
31-12-2015 31-07-2016 16-08-2016 16 d late 2016-44800474

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
Long-established
Founded in 1996, 30 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.1% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Long track record Annual accounts: weaker financial profile +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€-30k+36.1%
Working capital€15k-65.6%

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 31-07-2025 with the NBB · fiscal year 2024 · micro
€-50k€0€50kOperating result 2020: €-17k€-17kNet result 2020: €31k€31kOperating result 2021: €55k€55kNet result 2021: €53k€53kOperating result 2022: €9k€9kNet result 2022: €8k€8kOperating result 2023: €-28k€-28kNet result 2023: €-47k€-47kOperating result 2024: €-25k€-25kNet result 2024: €-30k€-30k20202021202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
stable Equity: stable across 7 fiscal years (±0.4%/year).
€250k€300k€350k€400k2025: €336k (€305k - €368k)2026: €335k (€285k - €385k)2027: €333k (€264k - €403k)2018: €346k2019: €345k2020: €326k2021: €379k2022: €386k2023: €339k2024: €309k2018201920202021202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 70, Head offices & management consulting · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 55.0% 60.6%
better than 44% of 12464 sector peers
Net result €-30k €31k
better than 5% of 12466 sector peers
Equity €309k €63k
better than 91% of 12472 sector peers
Gross operating margin €-10k €52k
better than 5% of 12452 sector peers
Total assets €562k €124k
better than 90% of 12465 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P44
2020: P55 · n=13712021: P60 · n=34652022: P61 · n=68462023: P52 · n=100762024: P44 · n=124642020 2024
Weakening position over 2020-2024 · n=1371-12464
Net result P5
2020: P9 · n=13712021: P77 · n=34642022: P28 · n=68452023: P5 · n=100702024: P5 · n=124662020 2024
Weakening position over 2020-2024 · n=1371-12466
Equity P91
2020: P84 · n=13732021: P92 · n=34702022: P94 · n=68542023: P93 · n=100832024: P91 · n=124722020 2024
Stable position over 2020-2024 · n=1373-12472
Gross operating margin P5
2020: P10 · n=13692021: P73 · n=34552022: P34 · n=68332023: P5 · n=100562024: P5 · n=124522020 2024
Weakening position over 2020-2024 · n=1369-12452
Describes the position versus peers, not a forecast.
EBITDA
€-13k
+50.4% 18-24
Net profit
€-30k
+36.1% 18-24
Cash flow
€-17k
+60.9% 18-24
Total assets
€562k
-0.8% 18-24
Equity
€309k
-8.9% 18-24
Working capital
€15k
-65.6% 18-24
Income taxes
€5k
-68.5% 18-24
Debt
€200k
+16.0% 18-24
Debt ≤ 1y
€103k
+55.5% 18-24
Debt > 1y
€97k
-8.8% 18-24
Current ratio
1.15
-30.9% 18-24
Quick ratio
1.15
-30.9% 18-24
Solvency
55.0%
-8.1% 18-24
Debt / equity
0.65
+27.3% 18-24
ROE
-9.7%
+29.9% 18-24
ROA
-5.4%
+35.6% 18-24
Interest coverage
-9.56
-39.0% 18-24
Figures by fiscal year
Fiscal year2024
Depositmicro
Revenue-
EBITDA€-13k
Net profit€-30k
Cash flow€-17k
Staff costs-
Income taxes€5k
Dividends-
Total assets€562k
Equity€309k
Debt€200k
of which ≤ 1y€103k
of which > 1y€97k
Working capital€15k
Employees (FTE)-
Ratios (computed)
2024
Current ratio1.15
Quick ratio1.15
Working capital ratio2.7%
Solvency55.0%
Debt / equity0.65
Long-term debt ratio0.31
Interest coverage-9.56
Gross margin-
Net margin-
ROA-5.4%
ROE-9.7%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€562k
Fixed assets 21/28€444k
Tangible fixed assets 22/27€444k
Current assets 29/58€118k
Amounts receivable within one year 40/41€5k
Investments 50/53€300
Cash & bank 54/58€23k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€562k
Equity 10/15€309k
Contributions / capital 10/11€20k
Reserves 13€242k
Accumulated profits (losses) 14€47k
Provisions & deferred taxes 16€53k
Amounts payable 17/49€200k
Amounts payable after one year 17€97k
Amounts payable within one year 42/48€103k
Trade debts payable within one year 44€5k
Income statement
Gross operating margin 9900€-10k
Operating result 9901€-25k
Financial charges 65€1k
Result before taxes 9903€-27k
Income taxes 67/77€5k
Net result for the period 9904€-30k
Result to be appropriated 9905€-22k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
55 / 100 Fair
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register
exact location from the address register On OpenStreetMap
3 companies at this address See who is registered here

Establishment units

1 location
PHARMACON BVBA
Filaturestraat 20, 9000 GentPersonenvervoer door de lucht
since 19962.075.091.207
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area8,288 m²
Buildings1
Building footprint849 m²
Volume (LiDAR)1 m³
Tallest building0.1 m

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44810K0054/00E003 Flanders 8,288 m² 1 · 849 m² 0.1 m
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Snowflake analysis

financial profile on 5 axes
Health55Profitability0Solvency80Growth32Stability100
53 / 100

Mixed profile: strong on stability, weaker on profitability.

All 5 axes are computed from data Checked has read.

Health 55
Profitability 0
Solvency 80
Growth 32
Stability 100

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies70200Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering70220Overige adviesbureaus op het gebied van bedrijfsvoering en beheer74142
Primary activity highlighted.
Names & trade names
Legal nameNL PHARMACON
Registered office
Filaturestraat 20 bus 301
9000 Gent, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.